
Soleno Therapeutics SLNO
$ 52.99
0.08%
Quarterly report 2026-Q1
added 05-07-2026
Soleno Therapeutics Accounts Payables 2011-2026 | SLNO
Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.Main types of accounts payable
| Type of liability | Example |
|---|---|
| To suppliers and contractors | Goods received but not yet paid for |
| Taxes and fees | VAT, income tax, etc., not paid on time |
| Salaries | Employee wages not paid |
| To budgets | Insurance contributions to funds not paid |
| To founders | Founders provided borrowed funds |
| To banks | Overdue loan payments |
| Other | Fines, penalties, forfeits, customer prepayments, etc. |
Impact on the company's financial performance
- Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios - Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence - Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals) - Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated
Annual Accounts Payables Soleno Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 12.4 M | 8.88 M | 3.15 M | 1.78 M | 3.25 M | 3.49 M | 2 M | 934 K | 633 K | 538 K | 695 K | 987 K | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 12.4 M | 538 K | 3.23 M |
Quarterly Accounts Payables Soleno Therapeutics
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 12.4 M | 8.14 M | 6.22 M | 5.48 M | 8.88 M | 6.24 M | 3.72 M | 8.02 M | 3.15 M | - | 3.44 M | 2.78 M | 1.78 M | 2.32 M | 2.41 M | 2.41 M | 3.25 M | 3.86 M | 3.35 M | 4.67 M | 3.49 M | 3.49 M | 3.49 M | 3.49 M | 2 M | 2 M | 2 M | 2 M | 934 K | 934 K | 934 K | 934 K | 633 K | 633 K | 633 K | 633 K | 411 K | 411 K | 411 K | 538 K | 695 K | 695 K | 695 K | 695 K | 987 K | 987 K | 987 K | 987 K | 57.7 K | 58 K | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 12.4 M | 57.7 K | 2.64 M |
Accounts Payables of other stocks in the Diagnostics research industry
| Issuer | Accounts Payables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Burning Rock Biotech Limited
BNR
|
63.1 M | $ 18.56 | 10.74 % | $ 196 M | ||
|
Agilent Technologies
A
|
446 M | - | - | $ 34.4 B | ||
|
Castle Biosciences
CSTL
|
18.7 M | $ 18.88 | 4.02 % | $ 547 M | ||
|
Fulgent Genetics
FLGT
|
18.4 M | $ 16.19 | 1.44 % | $ 490 M | ||
|
Akumin
AKU
|
36.6 M | - | -17.87 % | $ 25.9 M | ||
|
Interpace Biosciences
IDXG
|
983 K | $ 1.8 | -5.26 % | $ 7.96 M | ||
|
Aspira Women's Health
AWH
|
1.24 M | - | -6.19 % | $ 10.5 M | ||
|
Accelerate Diagnostics
AXDX
|
4.5 M | - | -61.36 % | $ 2.46 M | ||
|
Biocept
BIOC
|
1.52 M | - | -13.05 % | $ 7.29 M | ||
|
CareDx, Inc
CDNA
|
9.99 M | $ 20.49 | -0.58 % | $ 1.09 B | ||
|
Chembio Diagnostics
CEMI
|
3.34 M | - | 0.22 % | $ 16.8 M | ||
|
Medpace Holdings
MEDP
|
28.1 M | $ 419.17 | -1.08 % | $ 12.1 B | ||
|
Check-Cap Ltd.
CHEK
|
790 K | - | - | $ 9.42 M | ||
|
Lantheus Holdings
LNTH
|
42.9 M | - | - | $ 6.5 B | ||
|
Mettler-Toledo International
MTD
|
267 M | $ 1 041.91 | 1.75 % | $ 21.5 B | ||
|
Myriad Genetics
MYGN
|
30 M | $ 3.62 | -2.95 % | $ 335 M | ||
|
HTG Molecular Diagnostics
HTGM
|
1.16 M | - | -20.0 % | $ 1.06 M | ||
|
Co-Diagnostics
CODX
|
1.88 M | $ 1.63 | 1.87 % | $ 2.17 M | ||
|
NeoGenomics
NEO
|
23.1 M | $ 8.36 | 1.21 % | $ 1.07 B | ||
|
National Research Corporation
NRC
|
1.17 M | $ 18.93 | 1.39 % | $ 424 M | ||
|
Natera
NTRA
|
31.1 M | $ 196.91 | 0.81 % | $ 19.4 B | ||
|
Global Cord Blood Corporation
CO
|
8.33 M | - | - | $ 399 M | ||
|
DermTech
DMTK
|
1.48 M | - | -11.32 % | $ 2.94 M | ||
|
Charles River Laboratories International
CRL
|
149 M | $ 159.12 | -2.29 % | $ 7.89 B | ||
|
Enzo Biochem
ENZ
|
1.38 M | - | -8.98 % | $ 14.8 K | ||
|
Exact Sciences Corporation
EXAS
|
176 M | - | - | $ 19.8 B | ||
|
Personalis
PSNL
|
13 M | $ 6.71 | 5.01 % | $ 599 M | ||
|
Guardant Health
GH
|
54.4 M | $ 98.66 | 0.19 % | $ 12.4 B | ||
|
Senseonics Holdings
SENS
|
4.06 M | $ 5.82 | 5.82 % | $ 243 M | ||
|
Heska Corporation
HSKA
|
16.4 M | - | - | $ 1.31 B | ||
|
ICON Public Limited Company
ICLR
|
173 M | $ 117.09 | -0.25 % | $ 9.66 B | ||
|
Illumina
ILMN
|
221 M | $ 143.24 | -1.21 % | $ 22.8 B | ||
|
QIAGEN N.V.
QGEN
|
72.7 M | - | - | $ 10.6 B | ||
|
Twist Bioscience Corporation
TWST
|
11.1 M | $ 52.95 | -2.65 % | $ 3.17 B | ||
|
Biomerica
BMRA
|
295 K | $ 2.41 | 7.11 % | $ 5.54 M | ||
|
Thermo Fisher Scientific
TMO
|
3.62 B | $ 448.21 | 0.49 % | $ 169 B | ||
|
Laboratory Corporation of America Holdings
LH
|
841 M | $ 254.02 | -0.16 % | $ 21.1 B | ||
|
Waters Corporation
WAT
|
104 M | $ 333.21 | -0.51 % | $ 19.8 B | ||
|
Celcuity
CELC
|
6.41 M | $ 134.72 | 8.23 % | $ 6.3 B | ||
|
Neogen Corporation
NEOG
|
79.6 M | $ 8.43 | -2.99 % | $ 1.83 B |